Literature DB >> 33283249

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.

Olivia Beaudoux1, Marine Ehret, Emilie Criquet, Joséphine Franceschi, Anne Durlach, Jean-Bapstiste Oudart, Laetitia Visseaux, Florent Grange.   

Abstract

Entities:  

Keywords:  KIT inhibitor; KIT mutation; mucosal melanoma; penile melanoma

Mesh：

Substances：

Year:  2021        PMID： 33283249      PMCID： PMC9364252          DOI： 10.2340/00015555-3715

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  8 in total

1.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

2.  KIT pathway alterations in mucosal melanomas of the vulva and other sites.

Authors:  Katarina Omholt; Eva Grafström; Lena Kanter-Lewensohn; Johan Hansson; Boel K Ragnarsson-Olding
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

3.  Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience.

Authors:  Ricardo Sánchez-Ortiz; Samuel F Huang; Pheroze Tamboli; Victor G Prieto; Greg Hester; Curtis A Pettaway
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

4.  Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.

Authors:  Klaus G Griewank; Henrike Westekemper; Rajmohan Murali; Monika Mach; Bastian Schilling; Thomas Wiesner; Tobias Schimming; Elisabeth Livingstone; Antje Sucker; Florian Grabellus; Claudia Metz; Daniela Süsskind; Uwe Hillen; Michael R Speicher; Scott E Woodman; Klaus-Peter Steuhl; Dirk Schadendorf
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531

Review 5.  The mutational landscape of mucosal melanoma.

Authors:  Kelsey W Nassar; Aik Choon Tan
Journal:  Semin Cancer Biol       Date:  2019-10-23       Impact factor: 15.707

6.  STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

Authors:  Julie Delyon; Sylvie Chevret; Thomas Jouary; Sophie Dalac; Stephane Dalle; Bernard Guillot; Jean-Philippe Arnault; Marie-Françoise Avril; Christophe Bedane; Guido Bens; Anne Pham-Ledard; Sandrine Mansard; Florent Grange; Laurent Machet; Nicolas Meyer; Delphine Legoupil; Philippe Saiag; Zakia Idir; Victor Renault; Jean-François Deleuze; Elif Hindie; Maxime Battistella; Nicolas Dumaz; Samia Mourah; Celeste Lebbe
Journal:  J Invest Dermatol       Date:  2017-08-24       Impact factor: 8.551

7.  Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.

Authors:  Claire Mignard; Aurélie Deschamps Huvier; André Gillibert; Anne Bénédicte Duval Modeste; Caroline Dutriaux; Amir Khammari; Marie-Françoise Avril; Nora Kramkimel; Laurent Mortier; Pierre Marcant; Thierry Lesimple; Caroline Gaudy-Marqueste; Candice Lesage; Laurent Machet; François Aubin; Nicolas Meyer; Nathalie Beneton; Géraldine Jeudy; Henri Montaudié; Jean-Philippe Arnault; Laetitia Visseaux; Sabiha Trabelsi; Mona Amini-Adle; Eve Maubec; Yannick Le Corre; Dan Lipsker; Ewa Wierzbicka-Hainaut; Noémie Litrowski; Andreea Stefan; Florence Brunet-Possenti; Marie-Thérèse Leccia; Pascal Joly
Journal:  J Oncol       Date:  2018-12-02       Impact factor: 4.375

8.  Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.

Authors:  Mélanie Saint-Jean; Clémentine Fronteau; Lucie Peuvrel; Amir Khammari; Emilie Varey; Gaëlle Quéreux; Brigitte Dréno
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.